Hence, our study broadens the potential therapeutic applications of clinically approved PHD2 inhibitors, potentially serving as promising drug candidates for addressing platelet agglutination and maintaining circulatory homeostasis, and PHD2 inhibitors have shown promising effects in the treatment of atherosclerosis, as detailed in the supporting information (Supporting Information Figs. S6 and S7). This evidence concerns the gene EGLN1 and atherosclerosis.